Profound Medical Corp. PROF
Profound Medical Corp. (Nasdaq: PROF) is an oncology medical device company. Its next catalyst on record is TULSA-PRO: One year CAPTAIN clinical outcome data on track to be presented at RSNA 2026 in late November/early December 2026. (November 2026).
Upcoming catalysts
- November 2026TULSA-PRO — One year CAPTAIN clinical outcome data on track to be presented at RSNA 2026 in late November/early December 2026.
One year CAPTAIN clinical outcome data is on track to be presented at the Radiological Society of North America's 112th Scientific Assembly and Annual Meeting (RSNA 2026) to be held in Chicago, IL, November 29-December 3, 2026.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TULSA-PRO system | Prostate disease spectrum (cancer, BPH, salvage therapy) | device-combination | NA_NON_THERAPEUTIC |
| Sonalleve | Uterine fibroids, palliative pain treatment of bone metastases, osteoid osteoma | device-combination | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other oncology companies
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- Personalis, Inc. PSNL
- AnaptysBio, Inc. ANAB
- Alpha Tau Medical Ltd. DRTS
- Freenome, Inc. FRNM
- Burning Rock Biotech Ltd BNR
- Sensus Healthcare, Inc. SRTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.